With the increasing use of sodium-glucose cotransporter-2 inhibitors for type 2 diabetes and heart failure, clinicians need to understand how to treat euglycemic diabetic ketoacidosis (DKA), which is a potential side effect of the medication. The disease triad of euglycemic ketoacidosis, acute pancreatitis, and hypertriglyceridemia (HTG) has complex pathogenesis, and often the trigger of the triad is unknown. Here, we present an unusual case of euglycemic DKA in a transitioning transgender woman on canagliflozin who was treated with 10% dextrose and insulin infusions and apheresis. What makes our case unique is an added layer of complexity with her use of estrogen supplements contributing to HTG and gallstone formation, which could have set off the disease triad.
Keywords: acute pancreatitis; canagliflozin; estrogen supplements; euglycemic diabetic ketoacidosis; gallstone pancreatitis; hypertriglyceridemia; sglt2 inhibitors; terrible triad of endocrinology; transgender; transgender female.
Copyright © 2021, Tirthani et al.